{"id":"short-postimplantation-dual-antiplatelet-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Stent thrombosis"},{"rate":null,"effect":"Gastrointestinal bleeding"}]},"_chembl":{"chemblId":"CHEMBL5984914","moleculeType":null,"molecularWeight":"296.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dual antiplatelet therapy (DAPT) typically combines aspirin with a P2Y12 inhibitor (such as clopidogrel, prasugrel, or ticagrelor) to prevent stent thrombosis by inhibiting platelet aggregation through different pathways. Short postimplantation DAPT refers to a reduced-duration regimen (typically 1-3 months) rather than the standard 12 months, balancing the need for thrombotic protection against the increased bleeding risk associated with prolonged dual therapy.","oneSentence":"A treatment regimen that combines two antiplatelet agents for a shortened duration following coronary stent implantation to prevent thrombosis while reducing bleeding risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:35.589Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of stent thrombosis following coronary stent implantation"},{"name":"Acute coronary syndrome management with percutaneous coronary intervention"}]},"trialDetails":[{"nctId":"NCT05660811","phase":"PHASE4","title":"Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2022-09-28","conditions":"Atrial Fibrillation","enrollment":80},{"nctId":"NCT03445949","phase":"PHASE4","title":"Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2018-01-23","conditions":"Atrial Fibrillation","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"short postimplantation dual antiplatelet therapy","genericName":"short postimplantation dual antiplatelet therapy","companyName":"National Institute of Cardiology, Warsaw, Poland","companyId":"national-institute-of-cardiology-warsaw-poland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A treatment regimen that combines two antiplatelet agents for a shortened duration following coronary stent implantation to prevent thrombosis while reducing bleeding risk. Used for Prevention of stent thrombosis following coronary stent implantation, Acute coronary syndrome management with percutaneous coronary intervention.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}